These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
173 related articles for article (PubMed ID: 12228830)
1. Lipid formulations of amphotericin B for empirical treatment of fever and neutropenia. Frothingham R Clin Infect Dis; 2002 Oct; 35(7):896-7; author reply 897-8. PubMed ID: 12228830 [No Abstract] [Full Text] [Related]
2. Lipid formulations of amphotericins: are you a lumper or a splitter? Wingard JR Clin Infect Dis; 2002 Oct; 35(7):891-5. PubMed ID: 12228829 [No Abstract] [Full Text] [Related]
3. Lipid amphotericin B formulations as comparators in clinical trials. Powers JH; Albrecht R Clin Infect Dis; 2004 Jan; 38(2):305-6; author reply 306-7. PubMed ID: 14699471 [No Abstract] [Full Text] [Related]
4. ALERT: mix-ups between conventional and lipid formulations of amphotericin B can be extremely dangerous. Koczmara C; Richardson H; Hyland S; Lee CS; Hillebrand N Dynamics; 2011; 22(1):24-6. PubMed ID: 21469498 [TBL] [Abstract][Full Text] [Related]
5. Voriconazole versus liposomal amphotericin B for empirical antifungal therapy. Ullmann AJ; Heussel CP; Cornely OA N Engl J Med; 2002 May; 346(22):1745-7; author reply 1745-7. PubMed ID: 12041526 [No Abstract] [Full Text] [Related]
6. Voriconazole versus liposomal amphotericin B for empirical antifungal therapy. Apisarnthanarak A; Little JR; Tebas P N Engl J Med; 2002 May; 346(22):1745-7; author reply 1745-7. PubMed ID: 12041527 [No Abstract] [Full Text] [Related]
7. Amphotericin B: is a lipid-formulation gold standard feasible? Spellberg B; Witt MD; Beck CK Clin Infect Dis; 2004 Jan; 38(2):304-5; author reply 306-7. PubMed ID: 14699470 [No Abstract] [Full Text] [Related]
9. Design of clinical trials of empiric antifungal therapy in patients with persistent febrile neutropenia: considerations and critiques. Sobel JD Pharmacotherapy; 2006 Jun; 26(6 Pt 2):47S-54S. PubMed ID: 16716122 [TBL] [Abstract][Full Text] [Related]
10. Amphotericin B use in children: conventional and lipid-based formulations. Kuyucu N Expert Rev Anti Infect Ther; 2011 Mar; 9(3):357-67. PubMed ID: 21417875 [TBL] [Abstract][Full Text] [Related]
11. Lipid formulations of amphotericin B. Less toxicity but at what economic cost? Tollemar J; Ringdén O Drug Saf; 1995 Oct; 13(4):207-18. PubMed ID: 8573294 [No Abstract] [Full Text] [Related]
12. Voriconazole versus liposomal amphotericin B in patients with neutropenia and persistent fever. Powers JH; Dixon CA; Goldberger MJ N Engl J Med; 2002 Jan; 346(4):289-90. PubMed ID: 11807157 [No Abstract] [Full Text] [Related]
13. Empirical antifungal therapy--new options, new tradeoffs. Marr KA N Engl J Med; 2002 Jan; 346(4):278-80. PubMed ID: 11807153 [No Abstract] [Full Text] [Related]